CJC-1295 Ipamorelin: what the GH-axis literature actually measured

Before the details

This page reads the CJC-1295 Ipamorelin literature the way you would read a lab notebook: one finding at a time, each pinned to its source. There is no controlled trial of the blend itself, so the record is two stacks of single-compound studies plus the older research on combining a GHRH with a GH-releasing peptide. The strongest, most quotable numbers come from the CJC-1295 human pharmacokinetic studies; the cleanest mechanistic story comes from ipamorelin's selectivity work; and the rationale for using them together comes from synergy experiments dating to 1990. Where a number belongs to one compound and not the pairing, this page says so. Where human data simply do not exist — most of ipamorelin's pharmacokinetics, all of the fixed blend's — it says that too, plainly.

Cjc-1295 ipamorelin: the mechanism in two arms

CJC-1295 binds the GHRH receptor (a class-B G-protein-coupled receptor) on pituitary somatotrophs — the GH-making cells — raising cAMP through the Gs pathway and driving GH synthesis and release. Ipamorelin binds GHS-R1a, the ghrelin receptor, on the same cells, raising intracellular calcium through the Gq pathway. Two doors into the same room. Because the two arms act through independent, complementary pathways, co-stimulation produces a GH pulse larger than either agent alone, with a downstream rise in IGF-1 ^[3][4].

The receptor-level proof is direct: co-activating the cloned GHRH and ghrelin receptors in transfected cells produced a cAMP response roughly twice that of GHRH-receptor activation alone, pointing to genuine cross-talk between the two pathways ^[4]. The ghrelin arm also opposes somatostatin — the brake on GH secretion — which is part of why adding it amplifies the pulse rather than just duplicating the GHRH signal.

Cjc 1295 and ipamorelin: the long-acting half, measured in humans

The CJC-1295 half is the one with real human pharmacokinetic data. In healthy adults aged 21 to 61, single ascending subcutaneous doses of 30 or 60 µg/kg raised mean plasma GH 2- to 10-fold for six days or more and IGF-1 1.5- to 3-fold for nine to eleven days; after multiple doses, IGF-1 stayed above baseline for up to 28 days ^[1]. That multi-day profile is the defining property of the "with DAC" form.

A second human study added a crucial reassurance about how GH rose. During continuous CJC-1295 stimulation in healthy men, pulse frequency and amplitude were unchanged while basal (trough) GH rose roughly 7.5-fold, driving a 46% rise in mean GH and a 45% rise in IGF-1 ^[8]. In other words, sustained GHRH-receptor stimulation lifts the GH floor without abolishing the body's natural pulsing — a key pharmacodynamic point for any GHRH analogue. A follow-up proteomic analysis a week after injection found measurable downstream shifts in serum proteins such as apolipoprotein A1 and transthyretin, confirming the GH/IGF-1 axis had genuinely been activated systemically ^[10].

Ipamorelin cjc 1295: the selective GH-releasing half

Ipamorelin (sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2) earned its place in the pairing by being the first GH secretagogue that releases GH cleanly. Unlike GHRP-6 and GHRP-2, it did not raise ACTH or cortisol above GHRH-stimulated levels even at doses more than 200 times the ED50 for GH release, while matching GHRP-6's GH efficacy in conscious swine (swine ED50 about 2.3 nmol/kg) ^[2]. That selectivity is the headline: a strong, specific GH pulse without dragging the stress (HPA) axis along.

Its pharmacokinetics are rodent-only. In rats, ipamorelin's plasma clearance is roughly five-fold lower than GHRP-6, with 60 to 80% of the dose recovered in bile and urine ^[12]; the peak GH response lands about forty minutes after a dose. No validated human pharmacokinetic study of ipamorelin has been published — a real gap, and one this site does not paper over.

Cjc ipamorelin: the synergy evidence behind the pairing

The reason to combine a GHRH with a GH-releasing peptide at all comes from a 1990 study in eighteen normal adult men: submaximal GH-releasing-peptide doses (0.1 and 0.3 µg/kg) combined with GHRH (1 µg/kg) stimulated GH release synergistically, the two acting through independent mechanisms ^[3]. This is the foundational human evidence that a GHRP + GHRH combination produces supra-additive GH release — the mechanistic rationale for the CJC-1295 / ipamorelin pairing.

It is also the boundary of what can honestly be claimed. That experiment used related peptides at controlled intravenous doses, not CJC-1295 with ipamorelin at research-use subcutaneous doses. There is no peer-reviewed human pharmacology study of the pre-mixed combination itself. The synergy is real in principle and well documented for the class; its exact size and shape for this specific fixed pair are not characterized.

Growth hormone secretagogue: the class and its safety synthesis

A growth hormone secretagogue is any compound that prompts the body to secrete its own GH rather than supplying GH from outside — the category both halves of this stack belong to. The best available safety synthesis for the class comes from a 2018 review, which found these compounds well tolerated overall, with the chief safety concern being increased blood glucose from decreased insulin sensitivity, and long-term data on cancer incidence and mortality still needed ^[6].

That single sentence frames the whole risk picture: favorable short-term tolerability, a consistent glucose/insulin signal, and unresolved long-term oncologic questions. It is the most honest one-line summary of where the evidence stands for any GH secretagogue, this pairing included.

Ipamorelin vs sermorelin, and ipamorelin vs tesamorelin

Two comparisons come up constantly, and both turn on a single distinction: ipamorelin is a GH-releasing peptide (a ghrelin-receptor agonist), while sermorelin and tesamorelin are GHRH analogues — the same class as the CJC-1295 half, not the ipamorelin half.

Ipamorelin vs sermorelin. Sermorelin is a short-acting GHRH(1-29) analogue; ipamorelin works through the separate ghrelin pathway. They are not really rivals so much as the two arms a combination would pair — a GHRH analogue and a GHRP — which is exactly what the synergy literature recommends ^[3]. "Stronger" or "safer" between them is not answerable from head-to-head human data, because none exists.

Ipamorelin vs tesamorelin. Tesamorelin is a GHRH analogue with the strongest body-composition evidence in the GH-axis space: a 2026 meta-analysis of five randomized controlled trials found significant reductions in visceral adipose tissue (mean difference −27.71 cm²) and hepatic fat (−4.28%), increased lean body mass (+1.42 kg) and IGF-1, with no serious adverse events or glucose perturbation ^[7]. That is read-across context for the GHRH arm of this pairing, not data on ipamorelin or on the blend — tesamorelin is a different, separately studied compound, and the comparison is one of class, not of a tested equivalence.

The honest limits

Two facts bound everything above. First, most of ipamorelin's efficacy and dose-response data come from rodent models; human pharmacokinetics for ipamorelin are not formally published, and no controlled head-to-head human trial compares this combination with sermorelin, tesamorelin, or exogenous GH. Second, CJC-1295 (DAC) reached Phase 2 (ConjuChem) before development was discontinued — a Phase 2 program ended after an adverse event in one subject, reported as unrelated to the established mechanism — so even the better-studied half has no completed late-stage human program. The pairing is a well-reasoned read of solid single-component science. It is not a clinically validated product, and this log treats it as exactly that.